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Recurrence of high-grade prostate cancer after radiotherapy is a significant
clinical problem, resulting in increased morbidity and reduced patient sur-
vival. The molecular mechanisms of radiation resistance are being eluci-
dated through the study of microRNA (miR) that negatively regulate gene
expression. We performed bioinformatics analyses of The Cancer Genome
Atlas (TCGA) dataset to evaluate the association between miR-106a and
its putative target lipopolysaccharide-induced TNF-a factor (LITAF) in
prostate cancer. We characterized the function of miR-106a through
in vitro and in vivo experiments and employed transcriptomic analysis,
western blotting, and 30UTR luciferase assays to establish LITAF as a
bona fide target of miR-106a. Using our well-characterized radiation-resis-
tant cell lines, we identified that miR-106a was overexpressed in radiation-
resistant cells compared to parental cells. In the TCGA, miR-106a was sig-
nificantly elevated in high-grade human prostate tumors relative to inter-
mediate- and low-grade specimens. An inverse correlation was seen with its
target, LITAF. Furthermore, high miR-106a and low LITAF expression
predict for biochemical recurrence at 5 years after radical prostatectomy.
miR-106a overexpression conferred radioresistance by increasing prolifera-
tion and reducing senescence, and this was phenocopied by knockdown of
LITAF. For the first time, we describe a role for miRNA in upregulating
ATM expression. LITAF, not previously attributed to radiation response,
mediates this interaction. This route of cancer radioresistance can be over-
come using the specific ATM kinase inhibitor, KU-55933. Our research
provides the first report of miR-106a and LITAF in prostate cancer radia-
tion resistance and high-grade disease, and presents a viable therapeutic
strategy that may ultimately improve patient outcomes.
Abbreviations
A-T, ataxia telangiectasia; ATM, ataxia telangiectasia mutated; BCR, biochemical recurrence; DDR, DNA damage repair; DSB, double-
stranded break; IRR, radiation-resistant; LITAF, lipopolysaccharide-induced TNF-a factor; NGS, next-generation sequencing; RBL-2,
retinoblastoma-like protein 2; SA, senescence-associated; SBRT, stereotactic body radiotherapy; TCGA, The Cancer Genome Atlas;
UTR, untranslated region.
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1. Introduction
Prostate cancer is the most common nonmelanoma skin
cancer affecting men, and a leading cause of cancer-
related death worldwide. Radiation is a primary treat-
ment modality for localized prostate cancer, with equiv-
alent survival outcomes for low- and intermediate-risk
patients compared to radical prostatectomy (Hamdy
et al., 2016). However, despite administration of esca-
lated doses of radiation to the prostate, high-risk
patients with prostate cancer are at a significantly higher
risk of disease relapse (Chang et al., 2014). Therefore,
there is an unmet need to better characterize and treat
tumors at an elevated risk of relapse after radiotherapy.
MicroRNA (miR) are small (20–25 nucleotide) non-
coding RNA that negatively regulate gene expression.
miRNA are transcribed into long stem loop structures
that ultimately form a double-stranded RNA. The dom-
inant RNA strand is incorporated into the RNA silenc-
ing complex to facilitate target mRNA binding, and the
complementary strand is degraded (He and Hannon,
2004). miRNA decrease protein expression of their tar-
get mRNA by binding imperfectly to 6–7 nucleotides in
the seed sequence in the mRNA 30 untranslated region
(UTR) (He and Hannon, 2004). Transcript degradation
is the major outcome of miRNA-mRNA binding,
occurring through the 50-to-30 mRNA decay pathway
(Huntzinger and Izaurralde, 2011).
miRNA are involved in all cell processes and have
been of particular interest due to their role in cancer.
They have been implicated in cell cycle progression,
metastatic progression, and treatment response (Huang
et al., 2013, 2015; Mesci et al., 2017). Individual
miRNA can regulate thousands of cellular pathways
simultaneously (Huntzinger and Izaurralde, 2011).
Small perturbations in miRNA expression could lead
to harmful downstream effects resulting in tumorigene-
sis and treatment resistance. This multimodal action of
miRNA on cellular processing makes them a particu-
larly promising target for cancer treatment.
We identified miR-106a (dominant strand is miR-106a-
5p, henceforth referred to as miR-106a) from a next-gen-
eration sequencing (NGS) screen of radiation-resistant
(IRR) PC3 cells, as previously described by our group
(Huang et al., 2013). Bioinformatics analyses of The Can-
cer Genome Atlas (TCGA) dataset revealed that miR-
106a was significantly higher in prostate tumors com-
pared to normal prostate. miR-106a showed significantly
higher expression in high-grade prostate tumors com-
pared to low- and intermediate-grade tumors, suggesting
that miR-106a may be involved in disease progression.
We discovered that miR-106a increased survival and
growth after ionizing radiation using in vitro and in vivo
prostate cancer models. We also confirmed that miR-
106a targets lipopolysaccharide-induced TNF-a factor
(LITAF), to produce this radioresistant phenotype. In
addition, we found that high miR-106a and low LITAF
expression predict for decreased BCR-free survival at
5 years after radical prostatectomy. In this study, we
describe for the first time two novel players in prostate
cancer radioresistance: miR-106a and LITAF. We
describe a novel mechanism where miR-106a overexpres-
sion and LITAF knockdown upregulate ataxia telangiec-
tasia-mutated (ATM) expression. Inhibition of ATM
kinase activity with KU-55933 resensitized miR-106a-
overexpressing cells to radiation, highlighting a promising
therapeutic intervention for miR-106a radioresistant
prostate cancer.
2. Materials and methods
2.1. Bioinformatics analysis
Expression data and clinical information from 487
prostate tumor samples and 52 matched normal sam-
ples were downloaded from the TCGA (https://portal.
gdc.cancer.gov). Of these, 287 samples were Gleason
score ≤7 (low- and intermediate-grade) and 200 sam-
ples were Gleason >7 (high-grade) disease. Analyses
were carried out in the programming language R
(v3.4.0, Auckland, New Zealand). Two-sided Wilcoxon
tests were used to examine statistical significance for
group comparisons. Data visualization employed the
BPG package (v5.7.1, Toronto, ON, Canada) (P’ng
et al. in submission, https://www.biorxiv.org/content/
early/2017/06/26/156067).
For biochemical recurrence (BCR)-free survival anal-
ysis, 391 TCGA tumor samples showing BCR within
5 years were used. Expression values of miR-106a and
LITAF were dichotomized (high vs. low) with the cutoff
values showing the most discriminative power in the uni-
variate cox model for BCR-free survival. SURVMISC R
package (version 0.4.5, Pheonix, AZ, USA) was used to
optimized cutoff values. Kaplan-Meier method was used
to estimate survival distributions, and the relationship
between BCR-free survival and each variable (miR-106a
and LITAF) was analyzed with Wald test. The relation-
ship between BCR-free survival and four subgroups
(combinations of expressions of miR-106a and LITAF)
was analyzed with log-rank test.
2.2. Cell culture
PC3 and DU145 prostate adenocarcinoma cell lines
were purchased from the American Type Culture Col-
lection (ATCC, USA). Cell lines were maintained as
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previously described by our group (Huang et al., 2013)
and tested regularly for mycoplasma contamination
using the MycoAlertTM Mycoplasma Detection Kit
(Lonza, Mississauga, ON, Canada).
2.3. Transfection of miR-106a mimic and LITAF
siRNA
A total of 2 9 105 cells were seeded into 6-well plates.
Twenty-four hours later, miRNA mimics (5 lM) or 3-
sequence pooled siRNA (10 lM) (Shanghai Gene-
Pharma Co., Shanghai, China) were transfected into
cells using Lipofectamine 2000 Reagent (Invitrogen,
Thermo Fisher Scientific, Mississauga, ON, Canada)
and Opti-MEM I (1X) reduced serum media (Invitro-
gen), as per manufacturer’s recommendations. Cells
were collected at 24 h post-transfection for all experi-
ments. miRNA mimic and siRNA sequences can be
found in Table S1A.
2.4. Radiation
Radiation was performed using a Faxitron 43855F
X-ray Irradiator (Faxitron Bioptics LLC, Tucson, AZ,
USA). Radiation settings were as follows: 160 kV,
6.3 mA, for 1.1, 2.3, 3.5, 4.6, and 5.7 min for a radia-
tion dose of 2, 4, 6, 8, and 10 Gy, respectively.
2.5. RNA isolation
Cells were lysed. Total RNA enriched in miRNA and
mRNA was collected using miRVANA microRNA
isolation kit (Life Technologies, Thermo Fisher Scien-
tific) and RNeasy Mini Kit (Qiagen, Toronto, ON,
Canada), respectively. RNA concentration and purity
were determined using the Agilent 2100 Bioanalyzer
with the RNA 6000 Nano kit (Agilent Technologies
Canada Inc., Mississauga, ON, Canada).
2.6. qRT-PCR cDNA synthesis
miRNA was synthesized into cDNA using miSCRIPT
II RT Kit (Qiagen); mRNA was made into cDNA
using the SuperScript VILOTM kit (Invitrogen). Real-
time quantitative PCR was performed to analyze gene
expression using the miScript SYBR Green PCR
Kit for miRNA transcripts (Qiagen), and SYBR
Select Master Mix for mRNA transcripts (Life Tech-
nologies). Primer sequences are available in
Table S1B (Invitrogen). Gene expression was calcu-
lated based on the comparative Ct method by
Applied Biosystems StepOnePlus Real-Time PCR Sys-
tem (Thermo Fisher Scientific), and relative miRNA
and mRNA expression levels normalized to
SNORD61_11 (SNORD) and GAPDH, respectively.
2.7. Clonogenic survival assay
Mimic or siRNA-transfected PC3 and DU145 cells
were seeded in triplicate, irradiated, and stained as pre-
viously described (Huang et al., 2013). Number of
colonies (>50 cells) was counted, and surviving fraction
was determined from plating efficiency of radiation-
treated cells relative to mock-irradiated cells. Clono-
genic survival was represented in dose–response curves
by fitting relative surviving fraction to the linear quad-
ratic formula equation S = eaDbD2 using GRAPHPAD
PRISM 5.0 (GraphPad Software, San Diego, CA, USA)
(Huang et al., 2013). This experiment was performed
three separate times.
2.8. Proliferation assay
Mimic or siRNA-transfected cells were seeded in tripli-
cate in 6-well plates (0 Gy at 5 9 104 cells per well
and 8 Gy at 1 9 105 cells per well) and irradiated
24 hr later. Cells were trypsinized four days later
(0 Gy) or five days later (8 Gy), and viable cells were
measured with the Countess automated cell counter
(Invitrogen). The number of viable cells was averaged
among three biological replicates.
2.9. Cell cycle distribution
Cells were seeded at a density of 2 9 105 cells per 6-
well plate. Cells were transfected the following day
with control/miR-106a mimic and irradiated 24 hr
after transfection (PC3 at 6 Gy, DU145 at 10 Gy).
Cells were collected at 24 h and fixed as previously
described (Huang et al., 2013). FACS Calibur flow
cytometer (BD Biosciences, Mississauga, ON, Canada)
was used to capture 10 000 events per sample, and cell
cycle distribution was analyzed using FlowJo 10.0.4
(FlowJo LLC, Ashland, OR, USA). This experiment
was performed three separate times.
2.10. Cell senescence assay
Transfected cells were seeded in a 6-well plate (0 Gy at
1 9 105 cells per well and 6 Gy at 5 9 104 cells per
well) and irradiated 24 hr later. Cells were fixed and
stained (on day of mock irradiation for 0 Gy and
7 days after 6 Gy irradiation) for senescence-asso-
ciated (SA)-b-galactosidase using the Senescence b-
Galactosidase Staining Kit (Cell Signaling Technology,
1326 Molecular Oncology 12 (2018) 1324–1341 ª 2018 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
miRNA-106a and cancer radioresistance C. Hoey et al.
Whitby, ON, Canada) as per manufacturer’s instruc-
tions. A minimum of 250 cells (from at least four
nonoverlapping images) were counted per condition.
The percentage of SA-b-galactosidase-positive cells
was averaged among three biological replicates.
2.11. Western blotting
Cells were lysed with NP-40 lysis buffer, and total cell
proteins were collected as previously described (Huang
et al., 2013). Protein lysates (40 lg) were run on poly-
acrylamide gel (Bio-Rad, Mississauga, ON, Canada)
and transferred onto polyvinylidene fluoride membranes
(Thermo Scientific). Membranes were blocked with 5%
nonfat dry milk or 5% bovine serum albumin (Roche
Diagnostics, Mississauga, ON, Canada) in TBS Tween-
20 (TBS-T) as previously described (Huang et al., 2013).
After overnight primary antibody incubation, mem-
branes were washed with TBS-T and incubated with
horseradish peroxidase-conjugated secondary antibody.
Blots were visualized using ECL substrate (Bio-Rad).
All antibodies were purchased from Cell Signaling
Technology, with working concentrations used as per
manufacturer’s instructions. Each western blotting
experiment was performed in three biological replicates.
2.12. KU-55933
KU-55933 (Cat#: SML1109; Sigma-Aldrich, Oakville,
ON, Canada) was dissolved in DMSO, and cells were
treated with vehicle (DMSO) or KU-55933.
2.13. Target detection
Total RNA was collected from DU145 control and
DU145 miR-106a-transfected cells using RNeasy Mini
Kit (Qiagen). Gene expression analysis was performed
by The Centre for Applied Genomics (The Hospital
for Sick Children, Toronto, Canada) using an Affyme-
trix GeneChip Human Gene 2.0 ST array (Affyme-
trix, Thermo Fisher Scientific). Data were normalized
using the default parameters in Affymetrix Expres-
sion ConsoleTM Software 1.4. Genes downregulated to
0.8-fold in miR-106a compared to control were identi-
fied as possible targets. Tumor suppressor genes were
isolated and cross-referenced to miR-106a targets
yielded from a combination of in silico prediction algo-
rithms: miRwalk, miRDB, PITA, MicroT4, miRMap,
RNA22, miRanda, miRNAMap, RNAhybrid, miR-
Bridge, PICTAR2, TargetScan. Resulting mRNA were
checked for miR-106a binding using TargetScan in sil-
ico algorithm prediction software (Agarwal et al.,
2015), yielding 12 possible gene targets of miR-106a.
Gene expression of potential targets in cells transfected
with control or miR-106a mimic was assessed by qRT-
PCR.
2.14. LITAF 30UTR luciferase reporter assay
PC3 cells were transiently co-transfected with wild-type
or mutant (predicted miR-106a-LITAF seed sequence
binding site nucleotides were mutated) LITAF 30UTR
luciferase reporter plasmid, b-galactosidase-expressing
PCCALL2/anton vector (gift from J. Filmus labora-
tory), and control or miR-106a mimics. Cell lysates
were harvested 24 h later. Luciferase Assay Reagent
(Promega, Madison, WI, USA) was added, and fluo-
rescence was measured with a luminometer to quantify
firefly luciferase activity. b-galactosidase activity was
measured by absorbance at 405 nm using the Fil-
terMax F5 Microplate Reader. Firefly luciferase activ-
ity was normalized to b-galactosidase activity for
transfection efficiency control. This experiment was
performed three separate times.
2.15. Stable cell line generation
Pre-miR-106a was cloned into a pBabe-puro vector.
miR-106a-pBabe and empty-pBabe vector were trans-
fected into Phoenix-AMPHO retroviral packaging cell
line (ATCC) and incubated for 24 h. The same day,
2 9 105 DU145 cells were seeded into a 6-well plate.
The following day, 2 mL of viral media, 5 lg poly-
brene (Sigma-Aldrich), and 0.5 mL FBS were added
onto cells. Cells were spin transduced at 1000 g for
90 min at 37 °C. Three days later, transduced cells
were selected using puromycin (1 lgmL1) for
2 weeks to generate DU145-control or DU145-miR-
106a stable cell lines. miR-106a overexpression and
radioresistant phenotype were confirmed by qRT-PCR
and clonogenic survival assays, respectively.
2.16. Tumor xenografts and radiation response
in vivo
Six- to seven-week-old female athymic nude mice were
injected subcutaneously into the right flank with three
million DU145-control or DU145-miR-106a stable
cells and Matrigel. Tumors were measured three times
a week with calipers. Tumor volume was calculated
assuming an ellipsoid shape, using the formula: vol-
ume (mm3) = (length 9 width2)/2. When tumor vol-
umes reached an average of 100 mm3 per group, mice
were randomly assigned to mock irradiation or one-
time 6 Gy irradiation treatment, which is within the
range of ionizing radiation used for stereotactic body
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radiotherapy (SBRT) treatment of prostate tumors.
Our endpoint was defined as tumor volume reaching
300 mm3. All animal experimental procedures were
performed in accordance with the University of Tor-
onto and Sunnybrook Research Institute guidelines
using a peer-reviewed Animal Use Protocol. The Sun-
nybrook Research Institute Animal Care Committee
(SRI ACC) has approved the Animal Use Protocol
(AUP) for this study (AUP#: 14-509).
2.17. Immunohistochemistry
Tumor xenografts were sectioned into 5-lM-thick sec-
tions. Sections were stained for hematoxylin and eosin
(H&E) (Leica Biosystems, Concord, ON, Canada).
Necrotic areas were outlined on tumor sections and
quantitated as a percentage of total section area using
the IMAGEJ software (n = 3 tumors per group). Prolifer-
ation was (Bethesda, MD, USA) assessed by Ki-67
immunostaining and quantitated using IMAGEJ.
2.18. ATM promoter luciferase reporter assay
PC3 and DU145 cells were transiently co-transfected
with ATM promoter or control vector, b-galactosidase
PCCALL2/anton vector, and control/miR-106a mimic
or control/LITAF siRNA. Cell lysates were collected
24 hr after transfection, and luciferase activity was
assessed using the LightSwitch Luciferase Assay Sys-
tem (SwitchGear Genomics, Active Motif, USA).
ATM/control promoter luciferase constructs were used
with LightSwitchTM Luciferase Assay Reagent (Switch-
Gear Genomics). This was performed in three biologi-
cal replicates.
2.19. Statistical analysis
Statistical analysis was performed using the GRAPHPAD
PRISM v5.01 software (GraphPad Software). Unpaired,
two-sided Student’s t-tests were used to compare the
mean values between two groups. Data are represented
as mean values  SEM unless otherwise mentioned.
Statistical significance was defined as P < 0.05.
3. Results
3.1. miR-106a is overexpressed in human
prostate tumors and associated with biochemical
recurrence
We analyzed the TCGA dataset to determine whether
miR-106a was more abundant in prostate cancer (Cancer
Genome Atlas Research Network, 2015). We found that
miR-106a was significantly overexpressed in prostate
cancer (487 samples) compared to matched normal sam-
ples (52 samples; P = 7.66 9 1018; two-sided Wilcoxon
test; Fig. 1A). miR-106a showed significantly higher
expression in clinical high-grade (200 samples; Gleason
>7) compared to low- and intermediate-grade (287 sam-
ples; Gleason ≤7) tumors (P = 0.05; two-sided Wilcoxon
test; Fig. 1B). This suggests that miR-106a is involved in
prostate tumorigenesis and tumor progression.
We further analyzed the TCGA dataset to determine
whether miR-106a expression correlates with biochemi-
cal recurrence (BCR)-free survival at 5 years. Using
the Kaplan-Meier method, we determined that high
miR-106a expression is associated with lower BCR-free
survival at 5 years after radical prostatectomy (391
tumors; P = 0.06; Wald test; Fig. 1C). This suggests
that high miR-106a expression is associated with poor
patient outcomes.
3.2. miR-106a confers an aggressive and
radioresistant phenotype
To identify miRNA involved in radioresistant prostate
cancer, we measured miRNA abundance by NGS in
our PC3 IRR and parental cell lines (Huang et al.,
2013). We discovered that miR-106a was increased
2.63-fold in IRR cells relative to parental cells. We val-
idated that miR-106a is overexpressed in IRR cells
with qRT-PCR, and this was maintained after radia-
tion treatment (Fig. 2A). Further, we observed upregu-
lation of miR-106a in DU145 cells following 6 Gy
radiation at 30 min (Fig. S1). Chaudhry et al. (2013)
also showed upregulation of miR-106a expression in
human lymphoblast cells after radiation. Taken
together, these results suggest that miR-106a may play
an essential role in radiation response and survival.
To investigate the effect of miR-106a on radiation
survival, we performed clonogenic survival assays, the
gold standard assay for radiation survival analysis.
miR-106a overexpression significantly increased surviv-
ing fraction after radiation in both PC3 (6 Gy,
P < 0.05) and DU145 cells (4 Gy, P < 0.05; 6 Gy,
P < 0.05; 8 Gy, P < 0.01; Fig. 2B). Clonogenic sur-
vival is represented in a logarithmic scale. We per-
formed proliferation assays, and in support of
increased clonogenic survival, both cell lines overex-
pressing miR-106a showed significantly increased pro-
liferation with mock irradiation (0 Gy) and radiation
(8 Gy) (P < 0.05; Fig. 2C).
miR-106a’s clonogenic survival and proliferation
effects were mirrored by cell cycle distribution profiles.
Flow cytometry analysis showed significantly fewer
PC3 miR-106a cells in the G2/M phase compared to
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control after irradiation (P < 0.05; Fig. 2D). This sug-
gested that miR-106a allowed more cells to bypass the
G2/M checkpoint and continue through the cell cycle.
There were also fewer DU145 miR-106a cells in the
G2/M phase after radiation, although this did not
achieve significance (P = 0.144; Fig. 2D). In addition,
a higher percentage of PC3 and DU145 cells had
entered the S phase with miR-106a overexpression
compared to control (P < 0.05; Fig. 2D). This trend
was maintained following radiation, although this did
not achieve significance (PC3, P = 0.06; DU145,
P = 0.11; Fig. 2D). This is concordant with our prolif-
eration data, where miR-106a-transfected cells showed
significantly increased proliferation before and after
radiation (P < 0.05; Fig. 2C).
In addition to altering cell cycle distribution, miR-
106a’s effect on radiation survival could be attributed
to reduced cell death. The PI3K-Akt pathway is an
imperative cell survival pathway in radioresistance,
and we have previously shown that miR-95 can upreg-
ulate this pathway (Huang et al., 2013). However, in
the context of miR-106a, we did not observe a differ-
ence in Akt activation, indicating that upregulation of
this pathway is not contributing to radioresistance in
this context (Fig. S2). Considering that senescence is a
predominant form of cell death after radiation in solid
tumors (i.e., prostate) (Eriksson and Stigbrand, 2010;
Gewirtz et al., 2008; Mirzayans et al., 2013; Wu et al.,
2012), we evaluated miR-106a’s effect on senescence.
Senescence-associated (SA)-b-galactosidase assays
revealed there were significantly fewer cells undergoing
senescence in irradiated PC3 and DU145 miR-106a
cells compared to control (PC3, P < 0.001; DU145,
P < 0.001; Fig. 2E). There were very few senescent
cells (< 1%) in unirradiated PC3 and DU145 cells, and
no difference was seen between control and miR-106a
cells (data not shown). Invasiveness, in addition to
proliferation and reduced cell death, is a property of
aggressive tumors. Therefore, we assayed miR-106a’s
effect using the Matrigel invasion assay, but did not
observe a significant change (Fig. S3).
Due to its role in radiation resistance, we evaluated
miR-106a’s effects on DNA damage response (DDR).
The formation and resolution of c-H2AX foci (phos-
phorylated histone-2AX) following genotoxic stress is
a well-established approach to assay DNA double-
stranded break (DSB) repair. We therefore performed
immunofluorescence microscopy to quantitate the pro-
portion of c-H2AX foci between miR-106a-overexpres-
sing and control cells (Methods S1). We observed
increased percentage of high foci cells at 5 min follow-
ing radiation and resolution of high foci by 24 hr.
However, there were no significant differences between
control/miR-106a cells at any time point (Fig. S4).
This suggested that altered DDR was not responsible
for radiation resistance caused by miR-106a.
3.3. miR-106a increases tumor growth
radioresistance in vivo
To characterize the effects of miR-106a in vivo, we
evaluated tumor growth in athymic nude mice. Irradi-
ated DU145-miR-106a tumors displayed a trend
toward larger endpoint volumes compared to control
Fig. 1. miR-106a is aberrantly expressed in human prostate tumors. (A) Expression of miR-106a is significantly increased in prostate tumor
samples compared to normal prostate tissue (P = 7.669 1018; n = 487 tumor and n = 52 normal matched; two-sided Wilcoxon test). (B)
miR-106a expression is significantly higher in tumors with Gleason score (GS) >7 compared to GS ≤7 (P = 0.05; n = 287 for GS ≤7 and
n = 200 for GS >7; two-sided Wilcoxon test). (C) High miR-106a expression is associated with lower BCR-free survival at 5 years (391
tumors; P = 0.06; Wald test).
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Fig. 2. miR-106a promotes an aggressive phenotype in prostate cancer. (A) PC3 parental and radiation-resistant (IRR) cells treated with
mock irradiation (IR) (0 Gy) or 6 Gy IR, and analyzed for miR-106a expression by qRT-PCR. (B) Clonogenic survival assays were performed in
PC3 and DU145 cells transiently transfected with control/miR-106a mimic to assess survival after IR. Surviving fraction was fitted to the
linear quadratic equation and represented in logarithmic scale. Representative images of DU145 control/miR-106a mimic clonogenic plates
irradiated at 4 Gy and 6 Gy. (C) Proliferation of PC3 and DU145 control/miR-106a cells at 4d after mock-IR (0 Gy), and 5d after 8 Gy IR. (D)
Cell cycle profile of PC3 and DU145 control/miR-106a cells was assessed with mock-IR and 24 h after IR (6 Gy for PC3, 10 Gy for DU145).
(E) SA-b-galactosidase assay was performed with PC3 and DU145 control/miR-106a cells 7d after 6 Gy IR. Representative images show
PC3 control/miR-106a-irradiated cells stained for SA-b-galactosidase (scale bar = 100 lm). Mean, SEM and statistical significance are
denoted; *P < 0.05; **P < 0.01; ***P < 0.001; n = 3 biological replicates.
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tumors (volume: control = 1.38, miR-106a = 2.83;
P = 0.06; n = 7 per group; Fig. 3A/B). As previously
discussed, 6 Gy is within the range of ionizing radia-
tion used for SBRT treatment of prostate tumors.
SBRT requires five fractions; therefore, we would
expect the effect seen in our study to increase after
additional radiation fractions.
To assess cellular changes, tumors were excised once
they reached endpoint and processed for histological
analysis. H&E staining revealed a trend toward less
necrosis in DU145-miR-106a tumors irradiated at
6 Gy, compared to DU145-control tumors; however,
this did not achieve statistical significance (Fig. 3C).
No difference in necrosis was found between unirradi-
ated (mock) tumors. Ki-67 staining showed that
DU145-miR-106a tumors had significantly more pro-
liferative cells compared to DU145-control tumors
after 6 Gy (%Ki-67: control = 17.0989, miR-106a =
32.0722; P < 0.05; Fig. 3D). No significant difference
in %Ki-67-positive cells was seen between unirradiated
groups. Taken together, these in vivo results suggest
that miR-106a overexpression increases tumor growth
after radiation leading to a radioresistant and aggres-
sive phenotype.
3.4. miR-106a promotes radioresistance and
tumor aggression by targeting LITAF
To understand the mechanism by which miR-106a
confers radioresistance and tumor aggression, we first
Fig. 3. miR-106a increases tumor growth and radioresistance in vivo. (A) Tumor volume of DU145 control and miR-106a stable tumors
before irradiation (IR), relative to volume at first day tumors were palpable (n = 14 per group). No difference was seen between control and
miR-106a stable tumors (P = 0.46). (B) Endpoint (Day 37) measurement for DU145 control and miR-106a stable tumors relative to volume at
IR (Day 0) (n = 7 per group). A trend toward increased volume in DU145 miR-106a-stable compared to control tumors was seen after 6 Gy
IR (P = 0.06). (C) DU145-control and DU145-miR-106a tumors were stained with H&E. Areas of necrosis were outlined and quantified
relative to total section area. Representative images are shown below. (D) DU145-control and DU145-miR-106a tumors were stained for Ki-
67. Ki-67-positive nuclei were quantified and plotted. Representative images are shown below (scale bar = 200 lm). Mean, SEM, and
statistical significance are denoted; *P < 0.05.
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investigated genes previously reported as targets for
miR-106a. The critical PTEN tumor suppressor has
been reported as a miR-106a target. However, PTEN
is null in the PC3 prostate cancer cell model we used,
indicating that miR-106a is not promoting radioresis-
tance by targeting PTEN (Russell and Kingsley, 2003).
Retinoblastoma-like protein 2 (RBL-2) has been
described as a target of miR-106a in ovarian cancer
(Liu et al., 2013). We confirmed previous findings that
miR-106a decreases RBL-2 transcript and protein
levels (Fig. S5A). However, RBL-2 knockdown did
not recapitulate increased clonogenic survival or prolif-
eration after radiation seen with miR-106a in PC3 or
DU145 cells (Fig. S5B/C). Thus, miR-106a was not
acting through RBL-2 to confer radioresistance, so we
continued searching for miR-106a downstream targets.
We performed a mRNA abundance microarray
analysis using DU145 cells transfected with control/
miR-106a mimics. Affymetrix data were deposited to
the GEO database. Of the 12 tumor suppressor gene
candidates, five were previously described to be
involved in proliferation, cell death, or radiation
response in various cancer types: LITAF, RASSF2,
PHLPP2, RUNX3, and TP53INP1 (Huang et al.,
2009; Jiang et al., 2010; Sakakura et al., 2007; Sandor
et al., 2015; Shi et al., 2016; Wei et al., 2012; Yama-
mura et al., 2006; Zhou et al., 2011). Expression levels
between PC3 and DU145 control and miR-106a cells
were compared using qRT-PCR (Fig. S5D). RUNX3
and TP53INP1 were not consistently downregulated in
both cell lines. PHLPP2 is an Akt phosphatase (Jiang
et al., 2010); however, as miR-106a does not promote
radioresistance through upregulation of Akt signaling
(Fig. S2), we did not focus on PHLPP2 further.
RASSF2 is a pro-apoptotic effector protein in the
RAS/PI3K/Akt pathway, so similar to PHLPP2, we
did not focus on this gene any further (Donninger
et al., 2010).
Lipopolysaccharide-induced TNF-a factor mRNA
was significantly downregulated in PC3 and DU145
miR-106a cells relative to control cells (PC3,
RQ = 0.46, P < 0.01; DU145, RQ = 0.66, P < 0.05;
Fig. 4A), which was confirmed at the protein level
(Fig. 4A). To determine whether LITAF was a puta-
tive target of miR-106a, we evaluated the functional
interaction of miR-106a and LITAF 30UTR. We con-
firmed miR-106a had one predicted binding site in the
LITAF 30UTR using TargetScan. PC3 cells were tran-
siently co-transfected with wild-type LITAF 30UTR
luciferase reporter plasmid, and control or miR-106a
mimic. PC3 miR-106a cells showed significantly
decreased luciferase activity compared to PC3 control
(P < 0.001; Fig. 4B). PC3 cells co-transfected with
LITAF 30UTR containing mutations in the predicted
miR-106a binding site showed no significant difference
in luciferase activity between control and miR-106a
cells. This suggested that LITAF is a direct target of
miR-106a.
To identify whether LITAF is involved in radioresis-
tant prostate cancer, we evaluated whether LITAF
expression may also be perturbed in PC3 IRR cells
compared to parental. We discovered that LITAF was
decreased in PC3 IRR cells relative to parental cells
with and without radiation (0 Gy, P = 0.05; 6 Gy,
P < 0.01; Fig. 4C). LITAF expression showed the
opposite trend as miR-106a, providing further support
that miR-106a radioresistance is conferred through
LITAF knockdown.
Furthermore, we characterized the consequences of
LITAF knockdown with siRNA (Fig. S6) to confirm
that it recapitulated the phenotype of miR-106a over-
expression. LITAF siRNA-treated cells had a signifi-
cantly higher proportion of surviving cells following
radiation, compared to control PC3 cells (2 Gy,
P < 0.01; 4 Gy, P < 0.01; Fig. 4D) and DU145 cells
(8 Gy, P < 0.01; Fig. 4D). These cells also showed
increased proliferation after radiation compared to
control cells (PC3, P = 0.08; DU145, P < 0.01;
Fig. 4E), and a significantly lower percentage of cells
undergoing senescence (PC3, P < 0.05; DU145,
P < 0.01; Fig. 4F). Similar to miR-106a, PC3 LITAF
siRNA cells did not have any significant effect on
DNA DSB repair (Fig. S4).
TCGA dataset analysis revealed that LITAF was
significantly downregulated in prostate cancer com-
pared to matched normal samples (P = 0.02, two-sided
Wilcoxon test; Fig. 5A). LITAF showed significantly
lower expression in clinical high-grade (Gleason >7)
compared to low-grade (Gleason ≤7) tumors (P = 4.07
9 105, two-sided Wilcoxon test; Fig. 5B). This sug-
gests that LITAF downregulation, likely by miR-106a,
is involved in prostate cancer tumorigenesis and tumor
progression. Furthermore, using Kaplan-Meier sur-
vival curves, we determined that low LITAF expres-
sion is associated with decreased BCR-free survival at
5 years (391 tumors; P = 8.419 103; Wald test;
Fig. 5C). The combination of high miR-106a and low
LITAF was associated with the lowest BCR-free sur-
vival of all four subgroups (P = 0.004; log-rank test;
Fig. 5D).
Taken together, these results indicate that LITAF
is a target of miR-106a, and LITAF knockdown
phenocopies radioresistance seen in miR-106a-overex-
pressing cells. This also highlights a novel role for
LITAF in prostate cancer radioresistance and disease
progression.
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Fig. 4. Lipopolysaccharide-induced TNF-a factor is a target of miR-106a and confers a radioresistant and aggressive phenotype when
inhibited. (A) qRT-PCR of LITAF mRNA expression (normalized to GAPDH), and representative western blot of LITAF protein expression in
PC3 and DU145 control/miR-106a cells. (B) Wild-type (WT) or mutant (MT) LITAF 30UTR luciferase reporter assay in PC3 control/miR-106a
mimic cells with firefly luciferase activity normalized to b-galactosidase activity. (C) PC3 parental and radiation-resistant (IRR) cells treated
with mock irradiation (IR) (0 Gy) or 6 Gy IR, and analyzed for LITAF expression by qRT-PCR. (D) Clonogenic survival assays were performed
in PC3 and DU145 cells transiently transfected with control/LITAF siRNA to assess survival after IR. Surviving fraction was fitted to the
linear quadratic equation and represented in logarithmic scale. Representative image of DU145 control/LITAF siRNA clonogenic plate at 6 Gy
or 8 Gy. (E) Proliferation of PC3 and DU145 control/LITAF siRNA cells 5d after 8 Gy IR. (F) SA-b-galactosidase assay was performed with
PC3 and DU145 control/LITAF siRNA cells 7d after 6 Gy IR. Mean, SEM, and statistical significance are denoted; *P < 0.05; **P < 0.01;
***P < 0.001; n = 3 biological replicates.
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3.5. ATM is a downstream effector of miR-106a
and LITAF
Due to miR-106a and LITAF’s effects on senescence
and radiation survival, we evaluated senescence mark-
ers to understand their mechanism of radioresistance.
The key senescence markers p53, p16, p21, and pRb
are null or mutated in PC3 and DU145 cell lines
(Chang et al., 2014; Russell and Kingsley, 2003; Sobel
and Sadar, 2005). We therefore looked at ATM,
another marker of senescence (Herbig et al., 2004). We
performed qRT-PCR and western blot to evaluate
ATM expression in PC3 and DU145 cells treated with
control/miR-106a mimic, and control/LITAF siRNA.
We found that both miR-106a overexpression and
LITAF knockdown in PC3 and DU145 cells resulted
in significantly increased ATM transcript levels com-
pared to control cells (PC3: miR-106a, P < 0.001;
LITAF, P < 0.01; DU145: miR-106a, P < 0.05;
LITAF, P < 0.05; Fig. 6A). This was also seen at the
protein level in PC3 (Fig. 6B) and DU145 (not shown)
cells before and after irradiation. Considering this, we
co-transfected PC3 and DU145 cells with an ATM
promoter luciferase construct and miR-106a mimics.
We found that both cell lines overexpressing miR-106a
significantly increased ATM promoter activity com-
pared to cells treated with control mimic (PC3,
P < 0.05; DU145, P < 0.01; Fig. 6C). This suggests
that miR-106a and LITAF likely act to upregulate
ATM expression through transcriptional activation of
the ATM promoter.
Radiotherapy resistance can result from alterations
in engagement of cellular DDR. ATM is the initial
sensor of DNA DSBs following IR. However, as
described above, we did not find miR-106a or LITAF
to have any effect on DNA DSB repair (Fig. S4).
Therefore, we focused on the role of ATM in radiation
resistance through senescence.
KU-55933 is a highly specific ATM kinase inhibitor.
We confirmed inhibition of phospho-ATM with KU-
55933 at 2 lM with western blot after performing a
dose-response optimization study (Fig. 6D). ATM is
well known for its role in senescence, so we evaluated
whether KU-55933 treatment could resensitize miR-
106a cells to radiotherapy through induction of senes-
cence. When miR-106a-overexpressing cells were trea-
ted with KU-55933, the percentage of senescent cells
increased, and cellular levels of senescence were
restored to similar levels as parental cells (Fig. 6E).
We performed clonogenic survival assays treating
miR-106a-overexpressing cells with KU-55933 and
found that KU-55933 resensitizes miR-106a cells to
radiation (Fig. 6F). These results suggest that miR-
106a, acting through LITAF, upregulates ATM to
increase survival after radiation and induce radioresis-
tance (Fig. 7). miR-106a’s effect on prostate cancer
radioresistance could be therapeutically targeted
through inhibition of ATM kinase activity.
4. Discussion
Despite advances in radiotherapy, prostate cancer
recurrence is still a major clinical problem, particularly
in high-grade cancer. Thus, there is an urgent need to
understand the biology of radioresistant tumors.
miRNA play an imperative role in regulating hundreds
of pathways simultaneously within the cell (Huntzinger
and Izaurralde, 2011). By understanding how dysregu-
lated miRNA alter tumor biology, we can develop new
combination therapies to sensitize resistant tumors to
radiotherapy.
miR-106a is one of seven miRNA of the oncogenic
miR-17 family. Specifically, miR-106a has previously
been shown to be upregulated in various cancer types,
including gastric, ovarian, pancreatic, colorectal, nons-
mall cell lung, and prostate (Ak et al., 2014; Kim
et al., 2014; Volinia et al., 2006). Dysregulation of
miR-106a expression has been associated with
chemotherapy resistance and metastasis (Ak et al.,
2014; Kim et al., 2014; Li et al., 2014). Despite these
findings, miR-106a’s role in prostate cancer radiation
response is, to the best of our knowledge, unknown.
Analyzing the TCGA dataset (Cancer Genome Atlas
Research Network, 2015), we found that miR-106a is
significantly overexpressed in human prostate tumors
compared to normal controls, in agreement with Voli-
nia et al. (2006). An advantage to our analysis with
the TCGA dataset is the increased number of patient
samples available. We also discovered that increased
miR-106a expression correlated with higher Gleason
score, suggesting that miR-106a is involved in prostate
cancer tumorigenesis and progression. Tumors of high
Gleason score are more likely to recur following treat-
ment and are more resistant to therapies upon recur-
rence (Chang et al., 2014). Furthermore, high miR-
106a expression was found to be a predictor of
decreased BCR-free survival at 5 years after radical
prostatectomy. For miR-106a’s downstream target
LITAF, it was also found that low LITAF expression
is a predictor of significantly decreased BCR-free sur-
vival. Interestingly, when assessing the relationship
between BCR-free survival and the four subgroups
(i.e., combinations of expressions with miR-106a and
LITAF), we found that high miR-106a and low
LITAF expression was the strongest predictor of
shortest time to BCR. This suggests that miR-106a
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and LITAF may serve as putative radiotherapy
response biomarkers, in addition to adverse prognostic
biomarkers (i.e., high 106a + low LITAF) as seen in
TCGA radical prostatectomy cohort.
Consistent with these clinical findings, this study
found that miR-106a confers an aggressive and
radioresistant phenotype by increasing cell survival
and proliferation after radiation, both in vitro and
in vivo. This suggests that miR-106a plays a role in
radiation response and radioresistance in prostate can-
cer. miR-106a has been associated with radiation
response in other cancer types. miR-106a was upregu-
lated in a lymphoblast cell line after 2 Gy radiation
(Chaudhry et al., 2013), and in peripheral blood cells
Fig. 5. Lipopolysaccharide-induced TNF-a factor is aberrantly expressed in human prostate tumors. (A) LITAF shows the opposite trend as
miR-106a expression, with significantly lower expression in prostate cancer compared to normal tissue (P = 0.02; n = 487 tumor and n = 52
normal matched; two-sided Wilcoxon test). (B) LITAF shows lower expression in Gleason score (GS) >7 tumors compared to GS ≤7 tumors
(P = 4.07 9 10-5; n = 287 for GS ≤7 and n = 200 for GS >7; two-sided Wilcoxon test). (C) Low LITAF expression is associated with lower
BCR-free survival at 5 years (391 tumors; P = 8.41 9 103). (D) The relationship between BCR-free survival and four combinations of miR-
106a and LITAF expression is shown. High miR-106a and low LITAF expression show the lowest BCR-free survival (391 tumors; P = 0.004;
log-rank test).
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of leukemia or lymphoma patients after myeloablative
fractionated radiation (Templin et al., 2011). Addition-
ally, using histopathological analysis, Conde-Muino
et al. observed higher miR-106a expression in nonre-
sponders compared to responders in patients with
rectal cancer receiving chemoradiotherapy (Conde-
Muino et al., 2015).
We identified LITAF to be a novel target of miR-
106a, and its knockdown recapitulates miR-106a-
induced radioresistance. LITAF has previously been
Fig. 6. miR-106a and LITAF regulate ATM expression to confer radioresistance. (A) qRT-PCR for ATM mRNA expression (normalized to
GAPDH) in PC3 and DU145 control(m)/miR-106a(106a) mimic and control(si)/LITAF siRNA cells. (B) Representative western blot for
phospho-ATM (pATM), total ATM, and b-actin (loading control) in PC3 control/miR-106a mimic and control/LITAF siRNA cells at 0 Gy and
30 min after 6 Gy irradiation (IR). (C) ATM promoter luciferase in PC3 and DU145 control/miR-106a mimic cells. (D) Representative western
blot for pATM, total ATM, and b-actin from PC3 cells were treated with DMSO only (vehicle), 1, 2, 5, and 10 lM of KU-55933 2 hr before
exposure to 6 Gy IR, and baseline at 0 Gy with DMSO only. (E) SA-b-galactosidase assay was performed with DU145 control/miR-106a
cells 7d after 6 Gy IR. Cells were treated with DMSO and 2 lM KU-55933. Representative images show DU145 control/miR-106a cells after
6 Gy stained for SA-b-galactosidase with DMSO or KU-55933 (scale bar = 200 lm). (F) Clonogenic survival assays were performed with
DU145 cells transfected with control and miR-106a mimic. PC3 and DU145 cells were treated with DMSO or 2 lM KU-55933 (KU) ATM
inhibitor 2 h prior to 6 Gy or 8 Gy radiation, respectively. Mean, SEM, and statistical significance are denoted; *, P < 0.05; **, P < 0.01;
***, P < 0.001; n = 3 biological replicates.
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described as a tumor suppressor due to its ability to
decrease proliferation in vitro and decrease tumor
growth in an in vivo model (Zhou et al., 2011). How-
ever, it is best characterized for its role in inflamma-
tory response, as reviewed in J. Zhou et al. (2011).
LITAF is a DNA-binding protein and is well known
for its role as a transcriptional regulator of TNF-a
(Shi et al., 2016). ATM and TNF-a expression have
previously been correlated: It was shown that in apop-
tosis, TNF-a activated caspase-3, which cleaved and
downregulated ATM (Hotti et al., 2000; Smith et al.,
1999). As LITAF is a putative transcriptional activator
of TNF-a, this outlines a possible link between LITAF
and ATM. We also show LITAF is inversely corre-
lated with ATM expression, although in our model
this occurs independently of TNF-a. In addition,
because apoptosis is not a predominant form of cell
death after radiation in prostate cancer, it is unlikely
to be the mechanism underlying LITAF’s regulation of
ATM described in this study.
Interestingly, miR-106a did not alter DDR as would
be expected with targeting ATM. However, we noted a
significant decrease in senescence, the major form of
cell death after radiotherapy, and this is abrogated
with ATM inhibition. Limited knowledge of ATM’s
role in senescence and the unexpected results from our
study suggest senescence may be tissue dependent.
ATM dysregulation is common in cancer. MiRNA
are known to target DDR components, and those
inhibiting DDR machinery have been shown to sensi-
tize prostate cancer cells to radiation (Hatano et al.,
2015). For example, miR-421 and miR-18a target
ATM, with miR-421-induced ATM downregulation
recapitulating radiation sensitivity similar to that seen
in Ataxia telangiectasia (A-T) patients (Hu et al.,
2010). A-T is an autosomal recessive childhood neu-
rodegenerative disease that is caused by biallelic
mutation of ATM, leading to absence or deficiency of
ATM protein or kinase function (Taylor and Byrd,
2005). A-T patients show an extreme sensitivity to
radiation. When ATM is downregulated (i.e., by
miRNA) or mutated so it is no longer functional,
cells are sensitized to radiation, mimicking the
response of A-T patients (Truman et al., 2005). In
contrast, it has been shown that upregulation of
ATM leads to radioresistance in castrate-resistant
prostate cancer, allowing cells to repair radiation-
induced DNA damage (Mahajan et al., 2012). Angele
et al. also found that ATM protein was overexpressed
in prostate cancer tissue compared to normal prostate
using immunohistochemistry (Angele et al., 2004). In
addition, they found a trend toward increased ATM
expression in high-grade (Gleason 8–10) prostate
tumors compared to low- and intermediate-grade
(Gleason 6&7). Furthermore, the Human Protein
Atlas revealed that ATM is overexpressed in prostate
cancer (Uhlen et al., 2015). ATM overexpression has
been correlated with poor response to radiotherapy
and worse overall survival in rectal cancer and
advanced nasopharyngeal carcinoma patients (Ho
et al., 2016; Ko et al., 2016). High ATM protein
levels have been associated with radioresistance in
primary glioma, chordoma, and breast cancer cells
(Tribius et al., 2001; Yin and Glass, 2011; Zhang
et al., 2017). Fraser et al. found that somatic ATM
mutations are associated with poor prognosis in loca-
lized prostate cancer (Fraser et al., 2017). These
results support our data that upregulation of ATM is
a mode of radiotherapy resistance in aggressive
tumors. We discovered a novel role for miR-106a and
LITAF through upregulation of ATM expression.
Targeting ATM is a promising therapeutic avenue to
explore for radiosensitization. With the SA-b-galacto-
sidase and clonogenic survival assays, we found that
KU-55933 treatment resensitizes miR-106a-overex-
pressing cells to radiation by increasing senescence.
Consistent with our results, KU-55933 has previously
been found to induce senescence and cell death in
breast, lung, and colon cancer cells (Crescenzi et al.,
2008). Despite this, we cannot formally rule out that
KU-55933 does not also affect DDR at a later time
than was assayed in this study.
MiR-106a’s clinical utility as a promising biomarker
is beginning to be uncovered in various cancers. MiR-
106a has been upregulated in tissue samples and
biofluids. Biofluids (i.e., blood, urine, and stool) are
particularly promising for clinical translation, due to
their noninvasive nature. In colorectal cancer, miR-
106a was elevated in stool samples from patients with
adenomas and colorectal cancer compared to healthy
Fig. 7. Proposed model by which miR-106a confers radiation
resistance. miR-106a upregulates ATM expression through LITAF
knockdown, to inhibit senescence and confer radioresistance in
prostate cancer. KU-55933 has been identified as a therapeutic
intervention for miR-106a-induced radioresistance.
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controls (Link et al., 2010). In esophageal squamous
cell carcinoma, miR-106a upregulation in plasma was
shown to be a diagnostic marker as part of a six-
miRNA signature (Zhou et al., 2017). In a study of
patients with breast cancer, Wang et al. found that
miR-106a was upregulated in breast tumor specimens
and matched sera compared to normal controls (Wang
et al., 2010). In prostate cancer particularly, miR-106a
has been identified as a serum biomarker as part of a
miRNA signature to differentiate high- and low-risk
prostate cancer (Alhasan et al., 2016). Another study
that assessed a cohort of patients from Memorial
Sloan Kettering Cancer Centre showed that miR-106a
is enriched in serum of patients with African American
prostate cancer compared to serum of Caucasian
patients (Yates et al., 2017). African American men
are at a significantly higher risk for developing pros-
tate cancer and have decreased outcomes compared to
Caucasian men (Shenoy et al., 2016). With current
diagnostic tools limited to PSA and Gleason score, the
use of circulating miRNA could generate new predic-
tive and/or prognostic biomarkers for improved
patient outcomes. Future studies should investigate
further into miR-106a’s biomarker feasibility for pre-
diction of tumor radiation response and high-grade
disease.
5. Conclusions
This study has identified a new miRNA involved in
prostate cancer radiotherapy resistance. miR-106a is
significantly upregulated in human prostate tumors,
with increased expression in high-grade (Gleason 8–10)
compared to low- and intermediate-grade tumors
(Gleason 6&7). We also show for the first time a novel
role for LITAF in regulating radioresistance, where
knockdown of LITAF induces increased survival and
proliferation after radiation. LITAF expression shows
the opposite trend as miR-106a in the TCGA dataset,
and in addition, the combination of high miR-106a +
low LITAF expression predicts for BCR at 5 years
after radical prostatectomy. We propose a model
whereby miR-106a targets LITAF, resulting in ATM
upregulation and radioresistance. This may be inde-
pendent of ATM’s role in DDR. In addition, we have
identified KU-55933 as a potential therapeutic inter-
vention in combination with radiation, to radiosensi-
tize miR-106a-induced radiation-resistant prostate
cancer. Our findings identify miR-106a and LITAF as
novel modulators of radioresistance through ATM
upregulation and suggest that miR-106a may be a
promising biomarker for high-grade disease and
radioresistant prostate cancer.
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